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Introduction
Rare bleeding disorders (RBDs) are heterogeneous diseases that are mostly inherited in an autosomal recessive manner and occur due to the absence or defects of one or more clotting factors, including factor I (FI), factor II (FII), factor V (FV), combined FV and factor VIII (FVIII), factor VII (FVII), factor X (FX), factor XI (FXI), factor XIII (FXIII) and vitamin Kdependent clotting factors (VKCFD). Estimated prevalence of these disorders is 1:500,000 for FVII deficiency (FVIID) to 1:2 million for FII (FIID) and FXIII deficiency (FXIIID) worldwide (1) (2) (3) (4) (5) . Rare clotting factor deficiencies cause blocking of the coagulation cascade and the subsequently inability to form a clot, resulting in varying bleeding tendency (6, 7) .
Rare coagulation diseases occur as a result of mutations in the coagulation factor genes with two exceptions, combined FV and FVIII deficiency (CFV-FVIIID), and combined deficiency of vitamin K-dependent factors (FII, FVII, FIX and FX). The former exception is caused by mutations in gene-encoding proteins involved in intracellular transport of these factors and the latter occur due to the mutations of gene-encoding proteins involved in post-translational modifications and vitamin K metabolism (6) .
RBDs are categorized in two types. Type 1 deficiencies are more frequently characterized by concomitant reduction in plasma coagulation factor activity and levels. Type 2 deficiencies are qualitative defects. The level of the coagulation factors is normal, slightly reduced or elevated but their functional activity is reduced (7) .
The clinical manifestations that are common to all RBDs are excessive bleeding during or after invasive procedures such a surgery, circumcision and dental extraction, and mucocutaneous bleeding such as epistaxis, gum bleeding and menorrhagia (8) (9) (10) (11) (12) . Routine laboratory coagulation tests used for investigation and diagnosis of rare coagulation disorders, except FXIIID, are prothrombin time (PT) and activated partial thromboplastin time (APTT), thrombin time (TT), bleeding time (BT) and platelet count are normal (13) . Specific factor activity, used for precise detection of RBDs, and molecular analysis could be used for confirmation of diagnosis, but in a few cases an underlying mutation cannot be detected with current sequencing instruments (14, 15) . This study focuses on clinical presentations, management and molecular aspects of patients with RBDs in Iran.
Strategy of search
For this study all relevant English language papers were searched in Medline, using appropriate keywords including: recessive bleeding disorders in Iran, rare bleeding disorders in Iran, rare inherited disorders in Iran, factor 1 deficiency in Iran, Factor I deficiency in Iran, FI Deficiency 
Results
After an extensive search, a total of 46 articles were found. After careful assessment, six of the articles were excluded due to wide overlap with other selected studies and their study populations; and six were excluded due to duplication. Finally, 34 articles were selected for the study.
Rare bleeding disorders in Iran
Iran, a Middle Eastern country with a high rate of consanguinity, has a relatively high rate of recessive inheritance disorders. Several studies in Iran have revealed that country has a high rate of RBDs (16) (17) (18) . Iran has the highest global incidence of FXIIID and among the highest rates of FVIID (18, 19) . The real distribution pattern of RBDs is not established in Iran and few studies of Iranian patients with RBDs have been performed. Most of those studies were focused on clinical presentation. Molecular analyses of Iranian patients with RBDs were performed on some patients; the exact number is unclear, most of the studies were performed in three areas:
southeastern, southern and north-eastern Iran (16, 17, 20) .
Diagnosis of rare bleeding disorders in Iran
Diagnosis of RBDs in Iran is based on clinical presentation, family history and appropriate laboratory tests (Table 1 ) (2, 16). Table 1 . Routine and specific coagulation tests available in Iranian coagulation laboratories (2, 4, 5) Molecular analysis of patients with RBDs is not routinely performed in Iranian patients but molecular analyses are available for patients with FXIIID, especially in the southeast, which has the highest global incidence of the disorder. A few molecular studies were performed in Iranian patients with FID, FVD, FXD as well as CFV-FVIIID and FXID. No molecular study was performed in FVIID and FIID (4, (21) (22) (23) (24) (25) .
General coagulation tests Specific coagulation assays Prothrombin time (PT)
Clauss fibrinogen assay
Activated partial thromboplastin time (APT)
Factor II assay
Thrombin time (TT)
Factor V assay
Reptilase time (RT)
Factor VII assay
Kaolin clotting time (KCT)
Factor VIII assay
Mixed prothrombin time (Mixed PT)
Factor X assay
Mixed activated partial thromboplastin time (mixed APTT)
Factor XI assay
Clot solubility test -

Factor I deficiency
A few cases of congenital fibrinogen disorders have been reported, including nine, eight and two patients from southern, southeastern and north-eastern Iran. All patients from southeastern and northeastern Iran had hypofibrinogenemia and afibrinogenemia respectively, whereas in southern Iran, of nine patients with fibrinogen disorders, only two were specifically determined to have afibrinogenemia. All patients from southeastern and northeastern Iran, and two patients with afibrinogenemia from southern Iran, were negative for blood-borne diseases. Eight patients from the southeast and two patients with afibrinogenemia from the northeast received cryoprecipitate as prophylaxis. Clinical presentations of two later patients, including a 17-year-old, presented with ecchymosis, menorrhagia and post-dental extraction bleeding; the second patient was a 30-year-old male with ecchymosis and hemarthrosis (16) (17) (18) . Recently an Iranian nine-day-old baby with umbilical cord bleeding has been reported (5). Molecular analysis of three Iranian patients with afibrinogenemia led to the identification of a 3282C→T nonsense mutation in exon II of the fibrinogen Bβ-chain gene. In two of the three patients, two small deletions, including 4209delA and 4220delT in exon 5 of the fibrinogen Aα-chain gene, also were observed (21).
Prothrombin deficiency
A few studies were performed in Iranian patients with prothrombin deficiency; no data about the molecular mechanisms of FIID are available for Iranian patients. Several reports are available about the spectrum of RBDs in different parts of Iran, but no patients with FIID were reported from southern and northeastern Iran and only one patient with this factor deficiency was reported from northwestern Iran (17, 18, 26) . Only three patients with FIID were reported from the 
Combined Factor V-VIII deficiency
Ninety-five Iranian patients with CFV-FVIIID were found in the literature but the origin of some patients was not mentioned. Because of this, an overlap may be present in reported cases (28 cases) (16) . Out of 95 cases, 28, 12, 4 and 2 cases were reported from northeast, south, southeast and northwest Iran; origin of the rest was not specified. Among Iranian patients, epistaxis and post-dental extraction bleeding are the most common presentations. Most reported cases had both FV and FVIII activity levels between 5% to 20%. Molecular analysis of twelve patients with CFV-FVIIID revealed that, in these patients, splice site mutation is the most common form of gene defect. Frameshift and nonsense mutations are other gene defects among Iranian patients (16-18, 22, 32-36) ( Table 2) . 
Factor VII deficiency
Factor X deficiency
In prophylaxis (42) . A few molecular studies were performed on Iranian patients with FXD; full molecular characteristics of these patients has been previously reported. Briefly, the most
common FX gene mutations in Iranian patients are missense mutations and splice-site mutations.
Most of the FX gene mutations are new and unique to a patient or a family (43) ( Table 3) .
Factor XI deficiency
Although 152 Iranian cases with FXID were reported by the WFH in 2013, literature review shows a significantly lower number: and only one and two cases with FXID were reported from southeastern and northeastern Iran (16, 17) . Seven cases with FXID were reported in northern
Iran and in a study of 502 bleeding disorders in southern Iran, five cases with FXID were detected. Among them, a causative mutation was detected only in 2 patients without inhibitor development (20) . In a study on 38 Iranians, without definitive origin of the patients, oral cavity bleeding, post-operative bleeding and epistaxis as well as hemarthrosis and hematoma were reported as clinical presentations. (44) ( Table 3) .
A clear relationship between FXI activity and plasma level with severity of clinical presentation in Iranian patients was not observed and this issue was reported (44) . Table 2) .
Factor XIII deficiency
Combined Factor X and Factor VII
Three Iranian patients with CFVII-FXD were reported; in two cases underlying mutations were detected in both factors' genes and the third one was not molecularly assessed. Unlike in CFV-VIIID, all three patients with CFVII-FXD had severe bleeding episodes such as umbilical cord bleeding, GI bleeding and hematoma as well as menorrhagia (45, 46) . A very rare case with combined FVII-FXIII deficiency was reported from the southeast of Iran (45) .
Discussion
In Iran, with its high rate of RBDs, only a few specialized centers have the resources and the expertise to diagnose RBDs. Furthermore, for many of these disorders there are no treatments available to their residents. A significant example for this problem is Khash city, southeast Iran, which has the highest number of patients with FXIIID. Due to a lack of appropriate medical services in this city, they have to travel to Zahedan, the provincial center for medical facilities. This is difficult especially for those people in rural areas of Khash whose economic situation is poor. (7, 47, 48) Palla et al are investigating general features of RBDs (6).
Iran's high rate of consanguineous marriage results in a higher rate of these autosomal recessive bleeding disorders (7) . Iran has the highest global incidence of FXIIID and FVIID is more common in Iran than anywhere else (Table 3 ) (49). 
Conclusion
Due to the high rate of consanguinity, Iran has high rate of RBDs but the precise prevalence of these disorders and the molecular basis of most cases is not clear. Since a considerable number of these patients present life-threatening bleeding, molecular studies can be used for carrier detection and, therefore, prevention of the further expansion of these disorders and their fatal consequence. 
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